BLS Pharmaceuticals Limited · ASX:BLS
BLS Pharmaceuticals — Q1 FY2027 Earnings Presentation
13 slides from BLS Pharmaceuticals's earnings presentation, Oct 21, 2026
Slide 1: Q1 FY2027 Activities Update
rsonal use only Q1 FY2027 Activities Update Manufacturing scale. Commercial execution. International growth. ASX: BLS | October 2026
Slide 2: Disclaimer
DISCLAIMER This presentation (Presentation) has been prepared by BLS Pharmaceuticals Limited ABN 97 084 464 193 No party other than BLS has authorised or caused the issue, lodgement, submission, dispatch or provision (BLS or the Company). The information in this Presentation is of a general backgrou
Slide 3: Q1 FY27 At a Glance
Q1 FY27 AT A GLANCE Record quarterly revenue and positive operating cash flow to start FY27. rsonal use only Q1 FY27 REVENUE R E C O R D Q U AR T E R CASH RECEIPTS NET OPERATING $26.7m FROM CUSTOMERS CASH FLOW $22.4m $2.0m Q1 FY26: $12.9m Q1 FY26: -$4.1m +23% vs Q4 FY26 +91% vs Q1 FY26 (pcp) $26.7m
Slide 4: Record Revenue
RECORD REVENUE Q1 FY27 revenue of $26.7m, the highest quarter in BLS's history. rsonal use only QUARTERLY REVENUE ($ MILLION) +23% +91% vs Q4 FY26 vs Q1 FY26 $26.7m $21.3m $21.7m KEY DRIVERS $17.2m › Higher manufacturing volumes across Australian operations $14.0m › Continued growth in white-label a
Slide 5: Cash Flow Positive
CASH FLOW POSITIVE Operating cash flow positive while investing in capacity and international expansion. rsonal use only CASH RECEIPTS AND NET OPERATING CASH FLOW ($ MILLION) CASH AT 30 SEPTEMBER 2026 $12.7m Receipts from customers Net cash from operating activities $22.4m $20.9m $20.7m 30 June 2026
Slide 6: FY27 Guidance Reaffirmed
FY27 GUIDANCE REAFFIRMED A record first quarter, with full-year guidance reaffirmed. REVENUE ($ MILLION) FY27 REVENUE rsonal use only $105m to $115m $105m to $115m +42% to +55% vs FY26 FY27 guidance FY27 ADJ. EBITDA MARGIN¹ 23% to 26% $74.2m FY27 UNDERPINNED BY Increased utilisation of existing Aust
Slide 7: Inventory Supporting Growth
INVENTORY SUPPORTING GROWTH Inventory built through FY26 supports domestic and international supply commitments. rsonal use only INVENTORY AND QUARTERLY REVENUE ($ MILLION) INVENTORY AT 30 SEPTEMBER 2026 $17.5m Inventory (quarter end) Quarterly revenue $26.7m 30 June 2026: $17.8m $21.3m $21.7m INVEN
Slide 8: Market Opportunity
MARKET OPPORTUNITY Large pharmaceutical companies are investing in next-generation mental health therapies. RECENT TRANSACTIONS rsonal use only Eli Lilly / AtaiBeckley Through its unique license Up to US$3.8bn Agreed acquisition, announced July 2026. US$2.8bn upfront plus contingent value rights of
Slide 9: FY27 Strategic Priorities
FY27 STRATEGIC PRIORITIES Building on record FY26 performance and a strong start to FY27. rsonal use only Manufacturing Scale International Growth Increase utilisation of Australian Grow volumes across existing domestic and manufacturing capacity, production volumes international customers and execu
Slide 10: Board and Management Team
BOARD AND MANAGEMENT TEAM rsonal use only Anthony Ho Samuel Watson Jason Hine Edward Myer Angus Walker Guy Robertson Paul Mitchell Independent Non- Managing Director & Executive Director & Non-Executive Alternate Director to Company Secretary & CFO Australia Executive Chair CEO COO Director Edward M
Slide 11: Corporate Structure
CORPORATE STRUCTURE CAPITAL STRUCTURE SHARE PRICE PERFORMANCE (12 MONTHS) rsonal use only Share price A$1.11 +185% A$1.29 A$0.35 Shares on issue 230.30m 12-month share price 12-month high (18 Sep 2026) 12-month low (4 Dec 2025) change Options & performance rights 14.5m $1.40 Market capitalisation A$
Slide 12: Appendix: Select Financial Items
APPENDIX: SELECT FINANCIAL ITEMS Five-quarter summary ($ million, unaudited). rsonal use only $ million Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Revenue 14.0 17.2 21.3 21.7 26.7 Receipts from customers 12.9 18.4 20.9 20.7 22.4 Net cash from / (used in) operating activities (4.1) 2.5 1.2 6.3 2.0 NOTES
Slide 13: Contact
rsonal use only CONTACT BLS Pharmaceuticals Limited NWR Communications Sam Watson Melissa Tempra Chief Executive Officer Media & Investor Relations hello@blspharma.com melissa@nwrcommunications.com.au ASX: BLS | October 2026
BLS Pharmaceuticals — Q1 FY2027 Earnings Presentation on 6ix